Eris Lifesciences Ltd

Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarter EBITDA stood at Rs 252 crore, up 70% compared with Rs 148 crore posted in same quarter last year. EBITDA margin expanded to 35.8% in Q4 FY25 as against 26.9% in Q4 FY24. Revenue from domestic branded formulation (DBF) business jumped 25% YoY to Rs 602 crore in Q4 FY25. The organic base grew 10% to Rs 529 crore, while revenue from Biocon -2 stood at Rs 73 crore during the period under review. The company reported 22% organic growth in overall insulin revenue to Rs 300 crore despite significant product shortage in RHI throughout the year. On full year basis, the company's consolidated net profit declined 10.3% to Rs 351.84 crore on 44.6% increase in revenue from operations to Rs 2,879.26 crore in FY25 over FY24. On guidance front, for FY26, the company projects an annual revenue addition of Rs 200'300 crore to its overall insulin franchise, beginning October 2025, driven by the insourcing of insulin production at its Bhopal facility. This strategic move is expected to significantly enhance its insulin portfolio. In DBF business, the company anticipates revenue growth of 15% to 21%, translating to revenues in the range of Rs 2,900'3,050 crore. EBITDA for the segment is projected between Rs 1,070 crore and Rs 1,130 crore, with EBITDA margins maintained around 37%. Additionally, the company expects revenues from its Swiss Parentals division to range between Rs 375- 390 crore reflecting a growth of 15'20%. EBITDA for this segment is estimated between Rs 130 crore and Rs 135 crore, with an EBITDA margin of approximately 35%. The company plans to expand Eris-AMD, its new injectable facility, with a capital expenditure of Rs 100- 200 crore in FY26. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.Powered by Capital Market - Live

The key equity indices traded with limited losses in morning trade as investors engaged in mild profit booking despite supportive global cues. The Nifty traded below the 24,900 level. Market participants will closely monitor global trade developments and the ongoing Q4 earnings season, which are likely to influence sentiment in the coming days. Realty shares witnessed buying demand for fifth consecutive trading session. At 10:25 IST, the barometer index, the S&P BSE Sensex, declined 207.05 points or 0.25% to 81,852.37. The Nifty 50 index fell 44.90 points or 0.19% to 24,894.40. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index fell 0.27% and the S&P BSE Small-Cap index shed 0.06%. The market breadth was positive. On the BSE, 1,772 shares rose and 1,729 shares fell. A total of 207 shares were unchanged. Buzzing Index: The Nifty Realty index advanced 1% to 942.55. The index rose 8.8% in the five consecutive trading sessions. DLF (up 5.29%), Raymond (up 4.95%), Sobha (up 0.55%), Prestige Estates Projects (up 0.36%) and Godrej Properties (up 0.09%) advanced. On the other hand, Phoenix Mills (down 1.16%), Macrotech Developers (down 1.01%) and Brigade Enterprises (down 0.91%) declined Stocks in Spotlight: Eris Lifesciences rallied 3.53% after the company reported a 30.29% jump in consolidated net profit to Rs 92.01 crore on 28.38% increase in revenue from operations to Rs 702.60 crore in Q4 FY25 over Q4 FY24. Ashok Leyland added 1.18% after the company's board is scheduled to meet on 23 May to consider the proposal for the issue of bonus shares. Adani Ports & Special Economic Zone (APSEZ) shed 0.18%. The company's board will meet on 23 May to consider issuing non-convertible debentures (NCDs) via a private placement basis.Powered by Capital Market - Live

Net profit of ERIS Lifesciences rose 32.11% to Rs 93.84 crore in the quarter ended March 2025 as against Rs 71.03 crore during the previous quarter ended March 2024. Sales rose 28.38% to Rs 702.60 crore in the quarter ended March 2025 as against Rs 547.27 crore during the previous quarter ended March 2024. For the full year,net profit declined 10.26% to Rs 351.84 crore in the year ended March 2025 as against Rs 392.05 crore during the previous year ended March 2024. Sales rose 44.59% to Rs 2879.26 crore in the year ended March 2025 as against Rs 1991.30 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales702.60547.27 28 2879.261991.30 45 OPM %35.9227.12 -35.3333.89 - PBDT206.12130.55 58 804.33613.85 31 PBT128.8776.75 68 488.87431.34 13 NP93.8471.03 32 351.84392.05 -10 Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live

Eris Lifesciences has allotted 33,287 equity shares under ESOP on 06 March 2025. The paid-up share capital of the Company accordingly stands increased from Rs. 13,61,29,282/- (13,61,29,282 equity shares of Re. 1/- each) to Rs. 13,61,62,569/- (13,61,62,569 equity shares of Re. 1/- each). Powered by Capital Market - Live

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 06 February 2025, has recommended a Interim dividend of Rs.7.35 per share (i.e.735%), subject to the approval of the shareholders.Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live

Net profit of ERIS Lifesciences declined 18.60% to Rs 83.63 crore in the quarter ended December 2024 as against Rs 102.74 crore during the previous quarter ended December 2023. Sales rose 49.36% to Rs 722.12 crore in the quarter ended December 2024 as against Rs 483.48 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales722.12483.48 49 OPM %34.6636.30 - PBDT197.36161.59 22 PBT116.16115.87 0 NP83.63102.74 -19 Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live

The Board of Eris Lifesciences at its meeting held on 25 October 2024 has approved the execution of Binding Term Sheet with Levim Lifetech and its shareholders for the purpose of acquiring 30% stake in Levim Lifetech for an investment of Rs 54 crore at a pre-money equity valuation of Rs 126 crore. The acquisition is aimed at expansion of the company's biotechnology footprint across a wide range of products and technologies. Powered by Capital Market - Live